FULC Fulcrum Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FULC

Price (delayed)

$4.8

Market cap

$296.75M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.65

Enterprise value

$277.07M

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's proprietary product engine ...

Highlights
The company's EPS rose by 36% YoY and by 7% QoQ
The debt has contracted by 18% YoY and by 5% from the previous quarter
Fulcrum Therapeutics's quick ratio has increased by 21% YoY but it has decreased by 2.8% from the previous quarter
The equity has grown by 15% YoY but it has contracted by 7% from the previous quarter
The revenue has plunged by 76% YoY and by 14% from the previous quarter
Fulcrum Therapeutics's gross profit has plunged by 76% YoY and by 14% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.fulcrumtx.com
Peers: OMGA

Key stats

What are the main financial stats of FULC
Market
Shares outstanding
61.82M
Market cap
$296.75M
Enterprise value
$277.07M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.16
Price to sales (P/S)
113.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
105.79
Earnings
Revenue
$2.62M
EBIT
-$98.71M
EBITDA
-$96.46M
Free cash flow
-$88.05M
Per share
EPS
-$1.65
Free cash flow per share
-$1.42
Book value per share
$4.13
Revenue per share
$0.04
TBVPS
$4.51
Balance sheet
Total assets
$278.88M
Total liabilities
$23.42M
Debt
$11.5M
Equity
$255.46M
Working capital
$248.42M
Liquidity
Debt to equity
0.04
Current ratio
18.65
Quick ratio
18.38
Net debt/EBITDA
0.2
Margins
EBITDA margin
-3,683%
Gross margin
100%
Net margin
-3,769.1%
Operating margin
-4,224.7%
Efficiency
Return on assets
-35%
Return on equity
-38.5%
Return on invested capital
-40.3%
Return on capital employed
-37.3%
Return on sales
-3,769.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FULC stock price

How has the Fulcrum Therapeutics stock price performed over time
Intraday
5.26%
1 week
5.49%
1 month
50.94%
1 year
-26.72%
YTD
-34.07%
QTD
8.11%

Financial performance

How have Fulcrum Therapeutics's revenue and profit performed over time
Revenue
$2.62M
Gross profit
$2.62M
Operating income
-$110.65M
Net income
-$98.71M
Gross margin
100%
Net margin
-3,769.1%
The revenue has plunged by 76% YoY and by 14% from the previous quarter
Fulcrum Therapeutics's gross profit has plunged by 76% YoY and by 14% from the previous quarter
Fulcrum Therapeutics's operating margin has decreased by 20% from the previous quarter
The net margin has contracted by 17% from the previous quarter

Growth

What is Fulcrum Therapeutics's growth rate over time

Valuation

What is Fulcrum Therapeutics stock price valuation
P/E
N/A
P/B
1.16
P/S
113.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
105.79
The company's EPS rose by 36% YoY and by 7% QoQ
FULC's P/B is 58% below its 5-year quarterly average of 2.6
The equity has grown by 15% YoY but it has contracted by 7% from the previous quarter
The revenue has plunged by 76% YoY and by 14% from the previous quarter
The price to sales (P/S) is 62% higher than the last 4 quarters average of 66.4

Efficiency

How efficient is Fulcrum Therapeutics business performance
FULC's return on invested capital is up by 38% year-on-year and by 9% since the previous quarter
Fulcrum Therapeutics's ROE has increased by 30% YoY and by 3% from the previous quarter
Fulcrum Therapeutics's ROA has increased by 27% YoY and by 2.5% from the previous quarter
The company's return on sales fell by 17% QoQ

Dividends

What is FULC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FULC.

Financial health

How did Fulcrum Therapeutics financials performed over time
Fulcrum Therapeutics's quick ratio has increased by 21% YoY but it has decreased by 2.8% from the previous quarter
The current ratio has grown by 20% year-on-year but it has declined by 2.4% since the previous quarter
The debt is 96% less than the equity
The debt to equity is down by 33% year-on-year
The debt has contracted by 18% YoY and by 5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.